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Tick-Transmitted Infections in Transvaal:
Consider Rickettsia africae
To the Editor: We report a case of African tick-
bite fever (ATBF) in a 54-year-old French hunter
returning to France on 21 April 1997, after a 15-
day visit to Transvaal, South Africa. While
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traveling in the veld, the hunter removed (but
did not keep) two ticks from his left leg. Two days
later, he observed eschars at the bite sites.
Within 5 days, he had high fever (39.5°C) and
headache and decided to fly back to France,
where he was admitted to the Infectious Diseases
Department in the Hotel Dieu Hospital in
Clermont-Ferrand. The patients clinical symp-
toms were persistent fever, severe headache, and
two inflammatory eschars on the left leg.
Laboratory results were normal. On 22 April, an
acute-phase serum sample and eschar biopsy
were sent to our laboratory. The patient was
treated with 200 mg per day doxycycline for 10
days. His symptoms resolved. A second serum
sample was collected on 13 May.
Microimmunofluorescence was performed
as previously described (1). Although the
acute-phase serologic results were negative,
the convalescent-phase serum exhibited
antiR. africae and antiR. conorii titers of 16 for
immunoglobulin (Ig) G and 8 for IgM. Sera were
adsorbed with R. conorii and R. africae antigens
(2), and serologic testing and Western blot
analysis (1) were performed on the resultant
supernatants. Cross-adsorption of the convales-
cent-phase serum caused the homologous and
heterologous antibodies to disappear when
adsorption was performed with R. africae
antigens; only homologous antibodies disap-
peared when adsorption was performed with
R. conorii. Western immunoblot, performed with
the same adsorbed serum, indicated R. africae
infection by demonstrating a specific reactivity
pattern with R. africaespecific antigens in the
110-kDa to 145-kDa region (2). An inoculation
eschar biopsy specimen was injected into human
embryonic lung fibroblasts, according to the
centrifugation shell-vial technique (3). After 6
days incubation at 32°C, a Gimenez staining of
methanol-fixed human embryonic lung fibro-
blasts showed rickettsialike bacilli. The strain
was identified by direct immunofluorescence
performed on the cells with an antiR. africae
monoclonal antibody (4). Moreover, DNA was
extracted from the ground eschar biopsy
specimen and from 200 µL of shell-vial
supernatant, by using a QIAmp Tissue kit
(QIAGEN GmbH, Hilden, Germany), according
to the manufacturers instructions. These
extracts were used as templates with primers
complementary to a portion of the coding
sequence of the rOmpA encoding gene in a
polymerase chain reaction (PCR) assay (5), and
the base sequences of the resulting PCR products
were determined (5). The sequence obtained by
both methods was the same as the R. africae
sequence in Genbank (100% similarity).
Since first described in Africa in 1910, tick-
transmitted rickettsioses have been imputed to a
single rickettsial species, Rickettsia conorii,
although two distinct clinical illnesses have been
observed (6): an urban form in patients in contact
with dogs and their ticks (Rhipicephalus spp.)
characterized by fever, headache, myalgia,
cutaneous rash, and a lesion at the site of the tick
bite (7), and a rural form in patients in contact
with cattle or game and their ticks (Amblyomma
spp.) characterized by mild signs and frequent
lack of rash (8).
Although R. africae was initially isolated
from Amblyomma cattle ticks in 1973, the first
evidence of its pathogenic role in humans was
seen in 1992 in a patient who, after a tick bite,
had fever, an inoculation eschar, regional
lymphadenopathy, but no cutaneous rash (9).
Since then, an additional 20 cases of R. africae
related infections have been reported in travelers
returning from Zimbabwe and South Africa (2,10).
R. conorii has long been considered the only
African spotted fever group rickettsia, respon-
sible for both Mediterranean spotted fever and
ATBF. Since the first case was described (9),
most of the 20 reported cases of ATBF occurred
as outbreaks (2,10) in Europeans returning from
Zimbabwe and South Africa. The occurrence of
concomitant ATBF cases is unusual since
Mediterranean spotted fever is generally
sporadic and is likely related to the biologic
characteristics of the recognized vector of
R. africae, Amblyomma spp. ticks. While both
are nonnidicolous ticks, Amblyomma spp. and
Rhipicephalus spp. exhibit very different host-
seeking behavior (11). Amblyomma spp. are ticks
of cattle and wild ungulates, are not host-
specific, and can readily feed on humans; they
are hunter ticks and exhibit an attack
strategy (in response to stimuli they specifically
converge on nearby hosts). Rhipicephalus spp.
are dog ticks and vectors of R. conorii; very host-
specific, they exhibit an ambush strategy (they
are passive and remain quiescent in their habitat
until a vertebrate host passes). Up to 72% of
A. hebraeum are infected with Rickettsia-like
organisms, in particular R. africae (12);
Amblyomma spp. are widely distributed in rural
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areas in sub-Saharan Africa (13) and prevalence
of A. hebraeum ticks, incidence of ATBF cases,
and prevalence of R. africae antibodies have been
strongly linked (14). Rural Africans are also
commonly infected with R. africae, usually at a
young age (14). In Zimbabwe, Kelly et al. (15)
demonstrated that 55% of the tested human sera
had antibodies against R. africae.
 ATBF usually has specific clinical features:
shorter incubation period than for Mediterra-
nean spotted fever, multiple inoculation eschars
(related to the host-seeking behavior and host-
specificity of Amblyomma spp. ticks, which are
attack ticks [15]), regional lymphadenopathies,
frequent lack of cutaneous rash or a pale
vesicular eruption, and absence of complications
(2). Although only 22 proven cases have been
described so far (including the present case),
ATBF has been recognized as a commonly
encountered disease in southern Africa since
1900 (8,16). Epidemiologic and clinical features
indicate that several cases previously diagnosed
on the basis of serology results only as R. conorii-
caused may have been caused by R. africae.
Given the serologic cross-reactivity among
spotted fever group rickettsiae, microimmunofluo-
rescence, the easiest serologic method, may not be
sufficient for the etiologic diagnosis of a
rickettsial spotted fever. A definitive diagnosis of
ATBF requires either additional serologic
procedures, such as cross-adsorption or Western
blot, or the use of PCR or culture. As for PCR,
rOmpA-amplification possesses sufficient se-
quence heterogeneity among the spotted fever
group rickettsiae to be used as an identification
tool (5). The centrifugation-shell vial-cell culture
(3), used routinely in our laboratory, reliably
isolates strictly intracellular bacteria, including
rickettsia, from blood and tissue specimens,
especially eschar biopsies (the specimen of choice
for isolation procedures or genomic detection).
We noted cross-reactions between R. africae
and R. conorii. Cross-adsorption between anti
R. africae and antiR. conorii antibodies and
Western blots confirmed that the antibodies we
detected were directed specifically at R. africae.
Furthermore, both PCR and cell culture
confirmed the diagnosis of R. africae infection.
ATBF appears to be an important emerging
disease in visitors to rural areas of southern
Africa. R. africae should be considered a
potential pathogen in patients returning from
such areas who have fever, headache, multiple
inoculation eschars, or regional lymphadenopa-
thy after a tick bite.
Pierre-Edouard Fournier,* Jean Beytout,
and Didier Raoult*
*UniversitØ de la MØditerranØe, Marseille, France;
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Extended-Spectrum Beta-Lactamase-
Producing Salmonella Enteritidis in
Trinidad and Tobago
To the Editor: Salmonella Enteritidis, a
predominantly localized pathogen of the human
gastrointestinal tract, can become invasive in
very young, very old, malnourished, and
immunocompromised patients. In recent years,
S. Enteritidis has emerged as a major intestinal
pathogen in Trinidad and Tobago (population 1.2
million); in 1997, S. Enteritidis caused 79 (66%)
of 119 culture-confirmed salmonella infections,
in contrast to 18 (18%) of 99, 48 (47%) of 102, and
107 (61%) of 178 in 1994, 1995, and 1996,
respectively. Increased incidence of S. Enteriti-
dis infections has been reported worldwide (1,2).
Of 216 human S. Enteritidis isolates tested for
antimicrobial susceptibility between 1994 and
1996 in Trinidad, none were resistant to
cephalosporins, aminoglycosides, ampicillin,
trimethoprim-sulphamethoxazole, chlorampheni-
col, and norfloxacin/ciprofloxacin by the Kirby-
Bauer disk diffusion method, which uses the
National Committee for Clinical Laboratory
Standards (NCCLS) breakpoints (3).
Here we report an unusual isolate of
S. Enteritidis resistant to all penicillins and
cephalosporinsincluding third-generation
cephalosporins, gentamicin, tobramicin, and
trimethoprim-sulphamethoxazoleby the Kirby-
Bauer disk diffusion method. Amoxicillin-
clavulanate and piperacillin-tazobactam disks
gave zone sizes of 15 mm and 19 mm,
respectively, which are classified as intermedi-
ate in the NCCLS guidelines. This isolate was
recovered from the blood culture of a febrile,
nonneutropenic patient with multiple myeloma
on two occasions 24 hours apart in March 1998.
The isolate was sensitive only to ofloxacin and
imipenem. Admitted to the hospital with
compressed fracture of the spine for physio-
therapy in December 1997, the patient had
several febrile episodes and received several
courses of multiple empirically prescribed
antibiotics (cefotaxime, gentamicin, and
piperacillin). The patient had not traveled
abroad during the previous 6 months.
Because cephalosporin resistance in salmo-
nellae has not been reported before in the
Caribbean, we investigated the mechanism
behind this third-generation cephalosporin
resistance further. Using amoxicillin-clavulanate
in combination with ceftazidime, ceftriaxone,
and aztreonam, we performed the double disk
synergy test to determine whether this strain
was an extended-spectrum beta-lactamase
producer as described elsewhere (3); augmenta-
tion of the zone at the junction of amoxicillin-
clavulanate and aztreonam/ceftriaxone/
ceftazidime zones confirmed that indeed it was.
In the past few years, third-generation
cephalosporin resistance in S. Enteritidis has
been described in Europe (4), the United States
(5), Turkey (6), India (7,8), and Argentina (9).
Few reports exist of extended-spectrum beta-
lactamasemediated third-generation cepha-
losporin resistance in Salmonella spp. To our
knowledge, this is the first report of this type of
resistance among S. Enteritidis in the Caribbean.
This patient was treated with ciprofloxacin for 1
week; subsequent blood cultures were negative.
This unusual isolate highlights the need to
establish an antimicrobial resistance surveil-
lance network for Salmonella isolates, including
S. Enteritidis, to monitor the trends and new
types of resistance mechanisms in the Carib-
bean. An epidemiologic study of S. Enteritidis
infections is being planned to describe the extent
of the problem and to define risk factors and
vehicles of human infections in three Caribbean
countries, including Trinidad and Tobago.
B.P. Cherian,* Nicole Singh,* W. Charles,*
and P. Prabhakar*
*Port of Spain General Hospital, Port of Spain,
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